Azienda Ospedaliera Ordine Mauriziano Di Torino
Verified site
Turin, Italy
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The trial looks at people with newly diagnosed advanced ovarian cancer that is non‑HRD‑positive. After having received platinum‑based chemotherapy, participants may receive a maintenance treatment. The new drug being tested is Raludotatug Deruxtecan (MK-5909, R‑DXd), given by IV infusion, either alone or together with bevacizumab. These options are compared with the usual treatment that doctors give after chemotherapy, called standard of care.
The study’s purpose is to find out whether the new maintenance approach can keep the disease from getting worse longer and help participants live longer. Participants will receive the study medication every few weeks for up to about two years, and will have regular doctor visits, imaging scans that follow RECIST 1.1 criteria, and questionnaires that assess quality‑of‑life. The main outcomes measured are the time before the cancer progresses, known as progression‑free survival, and the length of overall survival, called overall survival. Throughout the trial, doctors will watch for any adverse events and record them.
The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.
14 criteria
21 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Turin, Italy
Coimbra, Portugal
Prague, Czechia
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is a medicine that helps stop new blood vessels from forming around tumors. By blocking these vessels, it can slow the growth of cancer. In this study, it is given through an IV infusion and is used either by itself or together with another drug to see if adding it improves the treatment results for women with newly‑diagnosed advanced ovarian cancer.
is an experimental cancer drug that carries a tiny amount of chemotherapy directly to cancer cells. It is also given by IV infusion. The trial is testing whether using this drug as a maintenance treatment after initial chemotherapy, with or without the addition of bevacizumab, can help patients live longer without the disease getting worse.
This medication is given as an intravenous infusion, where a liquid solution is slowly injected into a vein. It is an approved drug that is widely used and described in many medical studies. It is mainly used to treat several cancers, including ovarian cancer, by blocking a protein that helps tumors grow new blood vessels. Bevacizumab is a monoclonal antibody that binds to VEGF‑A, stopping the signal that creates new blood vessels, and it belongs to the anti‑angiogenic drug class.
This drug is also administered by intravenous infusion, delivered directly into the bloodstream as a solution. It is currently an investigational medicine that is being studied in clinical trials and is not yet approved for general use. It is being tested as a maintenance treatment for newly diagnosed advanced ovarian cancer, aiming to keep the disease from returning after initial chemotherapy. Raludotatug deruxtecan is an antibody‑drug conjugate that attaches a chemotherapy payload to an antibody that seeks out cancer cells, delivering the toxic agent directly to the tumor, and it is classified as a targeted cytotoxic therapy.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.